Graybug Vision (GRAY) Competitors $2.76 -0.01 (-0.36%) (As of 12/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrends GRAY vs. BLRX, PRPH, ATHE, FLGC, BTAI, SPRB, NERV, GLYC, TRAW, and NRXPShould you be buying Graybug Vision stock or one of its competitors? The main competitors of Graybug Vision include BioLineRx (BLRX), ProPhase Labs (PRPH), Alterity Therapeutics (ATHE), Flora Growth (FLGC), BioXcel Therapeutics (BTAI), Spruce Biosciences (SPRB), Minerva Neurosciences (NERV), GlycoMimetics (GLYC), Traws Pharma (TRAW), and NRx Pharmaceuticals (NRXP). These companies are all part of the "pharmaceutical preparations" industry. Graybug Vision vs. BioLineRx ProPhase Labs Alterity Therapeutics Flora Growth BioXcel Therapeutics Spruce Biosciences Minerva Neurosciences GlycoMimetics Traws Pharma NRx Pharmaceuticals BioLineRx (NASDAQ:BLRX) and Graybug Vision (NASDAQ:GRAY) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment, earnings and community ranking. Does the MarketBeat Community believe in BLRX or GRAY? BioLineRx received 490 more outperform votes than Graybug Vision when rated by MarketBeat users. Likewise, 72.39% of users gave BioLineRx an outperform vote while only 50.00% of users gave Graybug Vision an outperform vote. CompanyUnderperformOutperformBioLineRxOutperform Votes50672.39% Underperform Votes19327.61% Graybug VisionOutperform Votes1650.00% Underperform Votes1650.00% Do insiders & institutionals have more ownership in BLRX or GRAY? 1.6% of BioLineRx shares are owned by institutional investors. Comparatively, 49.9% of Graybug Vision shares are owned by institutional investors. 1.1% of BioLineRx shares are owned by company insiders. Comparatively, 7.9% of Graybug Vision shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is BLRX or GRAY more profitable? Graybug Vision has a net margin of 0.00% compared to BioLineRx's net margin of -90.57%. Graybug Vision's return on equity of -77.61% beat BioLineRx's return on equity.Company Net Margins Return on Equity Return on Assets BioLineRx-90.57% -163.37% -34.21% Graybug Vision N/A -77.61%-71.34% Which has more risk & volatility, BLRX or GRAY? BioLineRx has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500. Comparatively, Graybug Vision has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Do analysts prefer BLRX or GRAY? BioLineRx presently has a consensus target price of $9.00, indicating a potential upside of 4,333.50%. Given BioLineRx's stronger consensus rating and higher probable upside, equities analysts clearly believe BioLineRx is more favorable than Graybug Vision.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioLineRx 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Graybug Vision 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to BLRX or GRAY? In the previous week, BioLineRx's average media sentiment score of 0.00 equaled Graybug Vision'saverage media sentiment score. Company Overall Sentiment BioLineRx Neutral Graybug Vision Neutral Which has better earnings & valuation, BLRX or GRAY? Graybug Vision has lower revenue, but higher earnings than BioLineRx. BioLineRx is trading at a lower price-to-earnings ratio than Graybug Vision, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioLineRx$21.99M0.74-$60.61M-$0.22-0.92Graybug VisionN/AN/A-$35.60M-$24.23-0.11 SummaryBioLineRx beats Graybug Vision on 10 of the 15 factors compared between the two stocks. Ad ProsperityPubWhat most folks don’t know about oil (BIG missed opportunity)$1 Trillion… That’s how much Big Tech is set to spend on AI investment in the coming months—according to Goldman Sachs. This investment is driving an A.I. boom that’s being felt across many industries… Including a specific group of energy tickers since A.I. data centers use a massive amount of power. One of those tickers is CEG, up nearly 600% in the last 3 years… Combined with the upcoming presidential election, we have the recipe for a major shakeup in the market. You see, each time the U.S. elects a new president, one overlooked part of the energy sector tends to see a big move. Fact is… this energy niche is BOOMING.And expects this underappreciated niche to continue rallying well into 2026. Get Graybug Vision News Delivered to You Automatically Sign up to receive the latest news and ratings for GRAY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRAY vs. The Competition Export to ExcelMetricGraybug VisionPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.34M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-1.6010.5990.1317.19Price / SalesN/A196.061,116.25117.01Price / CashN/A57.1643.1037.85Price / Book1.655.094.784.78Net Income-$35.60M$151.83M$120.31M$225.60M7 Day Performance1.10%-2.14%-1.92%-1.23%1 Month Performance-20.00%-4.56%13.65%0.46%1 Year Performance-7.02%8.87%28.34%15.24% Graybug Vision Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRAYGraybug VisionN/A$2.76-0.4%N/A-10.0%$4.34MN/A-1.6027High Trading VolumeBLRXBioLineRx2.3119 of 5 stars$0.21-4.8%$9.00+4,105.6%-87.8%$17.11M$21.99M-1.0240Analyst ForecastHigh Trading VolumePRPHProPhase Labs3.1958 of 5 stars$0.70+8.3%$11.00+1,460.5%-86.8%$16.83M$12.75M-0.57130High Trading VolumeATHEAlterity Therapeutics2.5378 of 5 stars$2.26-5.8%$6.00+165.5%-15.4%$16.50MN/A0.0010News CoverageFLGCFlora Growth2.9322 of 5 stars$1.22-6.2%$5.00+309.8%-21.6%$16.31M$64.15M0.00280Positive NewsGap DownHigh Trading VolumeBTAIBioXcel Therapeutics4.0015 of 5 stars$0.38-7.8%$5.00+1,215.8%-88.5%$16.24M$2.28M-0.1790Negative NewsGap DownHigh Trading VolumeSPRBSpruce Biosciences3.8199 of 5 stars$0.38+0.2%$3.90+915.6%-80.5%$15.86M$10.09M-0.4120Analyst RevisionNERVMinerva Neurosciences3.4703 of 5 stars$2.20-0.5%$5.00+127.3%-67.0%$15.39MN/A-5.029Analyst ForecastNews CoverageGap DownGLYCGlycoMimetics4.2389 of 5 stars$0.24-0.8%$10.00+4,123.0%-89.0%$15.27M$10,000.000.0050News CoverageGap DownTRAWTraws PharmaN/A$4.89+5.2%N/AN/A$14.82M$230,000.000.0017Positive NewsGap UpNRXPNRx Pharmaceuticals3.3034 of 5 stars$1.21+0.4%$32.00+2,555.6%-96.5%$14.57MN/A-0.562News CoveragePositive News Related Companies and Tools Related Companies BLRX Competitors PRPH Competitors ATHE Competitors FLGC Competitors BTAI Competitors SPRB Competitors NERV Competitors GLYC Competitors TRAW Competitors NRXP Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GRAY) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Graybug Vision, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Graybug Vision With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
